Georgia
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.09 (1.48 - 2.83) | 2015 | Modelled | WHO |
| 2.5 (1.90 - 3) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 2.64 (2.22 - 3.14) | 2013 | Modelled | Schweitzer et al, 2015 |
| 2.9 (2.38 - 3.51) | 2017 | Survey/reported | Kasradze et al, 2017 |
| 1.48 (1.46 - 1.50) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1.61 (1.59 - 1.64) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.63 (1.61 - 1.66) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.66 (1.64 - 1.68) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.7 (1.67 - 1.72) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.73 (1.71 - 1.76) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.75 - 1.80) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.80 - 1.85) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.86 (1.84 - 1.89) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.9 (1.87 - 1.92) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.92 (1.90 - 1.95) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.95 (1.92 - 1.98) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.98 (1.95 - 2.01) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2 (1.97 - 2.03) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.02 (1.99 - 2.05) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.05 (2.01 - 2.08) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.08 (2.05 - 2.12) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.12 (2.08 - 2.15) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.15 (2.11 - 2.19) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.16 (2.12 - 2.20) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.16 (2.12 - 2.20) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.15 (2.11 - 2.19) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.14 (2.10 - 2.17) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.12 (2.09 - 2.16) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.11 (2.08 - 2.15) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.11 (2.07 - 2.15) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.11 (2.07 - 2.15) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.1 (2.06 - 2.14) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.1 (2.05 - 2.14) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.1 (2.05 - 2.14) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.6 (1.58 - 1.63) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.7 | 2021 | Survey/reported | Georgia National Center for Disease Control and Public Health, 2022 |
| 2.9 | 2015 | Survey/reported | Kasradze A et al, 2020 |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.26 (0.16 - 0.42) | 2015 | Modelled | WHO |
| 0.24 (0.21 - 0.28) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.31 (0.27 - 0.36) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.33 (0.28 - 0.37) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.34 (0.29 - 0.38) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.33 (0.29 - 0.38) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.33 (0.28 - 0.39) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.34 (0.29 - 0.39) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.34 (0.29 - 0.40) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.36 (0.30 - 0.41) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.37 (0.31 - 0.42) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.39 (0.32 - 0.44) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.44 (0.36 - 0.49) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.52 (0.44 - 0.58) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.62 (0.54 - 0.70) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.74 (0.64 - 0.83) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.85 (0.73 - 0.96) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.96 (0.82 - 1.08) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.08 (0.90 - 1.23) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.2 (0.97 - 1.39) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.32 (1.03 - 1.54) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.42 (1.09 - 1.69) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.52 (1.21 - 1.78) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.63 (1.34 - 1.88) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.73 (1.46 - 1.96) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.8 (1.55 - 2.03) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.58 - 2.06) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.58 - 2.06) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.57 - 2.06) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.54 - 2.06) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.8 (1.49 - 2.05) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.76 (1.42 - 2.04) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.03 | 2020 | Survey/reported | Georgia National Center for Disease Control and Public Health, 2022 |
| 0.06 (0.04 - 0.08) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 100,000 (76,000 - 117,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 54,203 (53,602 - 54,860) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 56,155 (55,501 - 56,921) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 57,186 (56,491 - 57,920) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,348 (57,500 - 59,244) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 59,901 (59,193 - 60,696) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 61,803 (61,016 - 62,715) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 63,688 (62,922 - 64,555) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 65,854 (65,058 - 66,692) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 68,168 (67,327 - 69,063) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 70,466 (69,548 - 71,455) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 72,563 (71,514 - 73,658) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 74,512 (73,519 - 75,566) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 76,528 (75,533 - 77,584) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 78,575 (77,565 - 79,661) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 80,651 (79,548 - 81,757) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 82,791 (81,564 - 84,011) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 85,373 (84,122 - 86,622) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 88,572 (87,166 - 89,897) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 91,995 (90,457 - 93,445) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 95,192 (93,461 - 96,770) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 97,741 (95,816 - 99,508) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 99,578 (97,741 - 101,332) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 101,024 (99,263 - 102,687) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 102,215 (100,543 - 103,877) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 103,320 (101,577 - 105,005) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 104,582 (102,830 - 106,397) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106,008 (104,242 - 107,828) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 107,366 (105,562 - 109,263) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 108,545 (106,634 - 110,507) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 109,441 (107,222 - 111,519) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 109,998 (107,546 - 112,320) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 78,000 | 2021 | Survey/reported | Georgia National Center for Disease Control and Public Health, 2022 |
| 80,000 | 2015 | Survey/reported | Kasradze A et al, 2020 |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 10 (7.31 - 13.50) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 8.97 (6.67 - 11.49) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.18 (6.85 - 11.83) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.3 (7.02 - 11.92) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.09 (6.81 - 11.65) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.25 (7.04 - 11.85) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.83 (6.72 - 11.24) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.76 (7.45 - 12.37) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.05 (6.82 - 11.46) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.65 (6.55 - 10.93) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.39 (7.99 - 13.23) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.71 (8.22 - 13.52) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.82 (8.40 - 13.69) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.18 (8.64 - 14.03) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.28 (8.69 - 14.03) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.64 (9.04 - 14.67) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.2 (8.76 - 13.89) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.36 (8.80 - 14.10) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.98 (8.55 - 13.90) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.12 (8.63 - 14.04) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.12 (8.62 - 14.14) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.1 (8.69 - 14.04) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.06 (8.53 - 14.08) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.89 (8.33 - 13.92) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.63 (8.06 - 13.75) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.94 (7.63 - 12.76) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.14 (7.82 - 13.08) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.42 (7.11 - 12.32) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.7 (7.40 - 12.61) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.03 (7.31 - 13.46) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.57 (7.21 - 12.63) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 800 | 2016 | Modelled | WHO |
| 494 (368 - 633) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 502 (375 - 647) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 504 (380 - 646) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 486 (364 - 623) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 487 (371 - 624) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 458 (349 - 583) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 441 (334 - 558) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 454 (342 - 575) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 480 (367 - 609) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 501 (385 - 638) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 507 (389 - 639) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 501 (389 - 634) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 508 (392 - 637) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 508 (394 - 640) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 502 (386 - 624) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 486 (377 - 604) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 472 (369 - 585) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 455 (354 - 576) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 455 (353 - 574) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 448 (351 - 566) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 435 (336 - 554) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 443 (343 - 563) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 424 (324 - 542) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 410 (311 - 531) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 388 (299 - 500) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 377 (290 - 484) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 351 (265 - 459) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 365 (279 - 475) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 354 (267 - 467) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 367 (268 - 493) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 367 (268 - 493) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of HepB birth dose
Newborns
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 94 | 2019 | Survey/reported | WHO/UNICEF |
| 97 | 2018 | Survey/reported | WHO/UNICEF |
| 94 | 2017 | Survey/reported | WHO/UNICEF |
| 94 | 2016 | Survey/reported | WHO/UNICEF |
| 93 | 2015 | Survey/reported | WHO/UNICEF |
| 95 | 2014 | Survey/reported | WHO/UNICEF |
| 80 | 2013 | Survey/reported | WHO/UNICEF |
| 92 | 2012 | Survey/reported | WHO/UNICEF |
| 93 | 2011 | Survey/reported | WHO/UNICEF |
| 95 | 2010 | Survey/reported | WHO/UNICEF |
| 73 | 2009 | Survey/reported | WHO/UNICEF |
| 99 | 2008 | Survey/reported | WHO/UNICEF |
| 99 | 2007 | Survey/reported | WHO/UNICEF |
| 97 | 2006 | Survey/reported | WHO/UNICEF |
| 93 | 2005 | Survey/reported | WHO/UNICEF |
| 92 | 2004 | Survey/reported | WHO/UNICEF |
| 90 | 2003 | Survey/reported | WHO/UNICEF |
| 80 | 2002 | Survey/reported | WHO/UNICEF |
| 69 | 2001 | Survey/reported | WHO/UNICEF |
| 97 | 2020 | Survey/reported | WHO/UNICEF |
| 95 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 94 | 2019 | Survey/reported | WHO/UNICEF |
| 88 | 2020 | Survey/reported | WHO/UNICEF |
| 85 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 31 (16 - 271) | 2015 | Survey/reported | Georgia National Centre for Disease Control and Public Health, 2015; Curatio International Foundation, 2015; Eurasia Harm Reduction Network, 2015 |
| 78 | 2021 | Survey/reported | Georgia Technical Adviosry Group |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.9 (3.10 - 4.80) | 2015 | Survey/reported | Curatio International Foundation, 2015 |
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HBV elimination goal
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based, Birth cohort
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 5.4 (4.60 - 6.40) | 2015 | Survey/reported | Hagan et al, 2015 |
| 4.2 (3 - 4.20) | 2015 | Modelled | Blach et al, 2017 |
| 3.65 (2.96 - 4.46) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.67 (2.97 - 4.45) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.67 (2.96 - 4.46) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.65 (2.98 - 4.43) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.64 (2.99 - 4.44) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.7 (3.06 - 4.46) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.84 (3.21 - 4.59) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.02 (3.40 - 4.74) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.17 (3.52 - 4.87) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.24 (3.58 - 4.95) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.25 (3.60 - 4.95) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.26 (3.61 - 4.96) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.26 (3.60 - 4.95) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.26 (3.59 - 4.97) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.26 (3.57 - 4.98) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.28 (3.60 - 5) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.32 (3.63 - 5.06) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.36 (3.67 - 5.11) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.39 (3.69 - 5.15) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.39 (3.68 - 5.17) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.33 (3.65 - 5.07) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.22 (3.52 - 4.96) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.08 (3.37 - 4.83) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.95 (3.23 - 4.76) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.87 (3.12 - 4.70) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.82 (3.09 - 4.67) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.77 (3.05 - 4.63) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.72 (3.01 - 4.55) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.67 (2.95 - 4.51) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.62 (2.91 - 4.48) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.48 (2.81 - 4.24) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1.8 | 2021 | Survey/reported | Georgia National Center for Disease Control and Public Health, 2022 |
| 5.4 | 2015 | Survey/reported | Hagan et al, 2019 |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.25 (0.90 - 1.27) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 8.9 | 2018 | Survey/reported | Averhoff A et al, 2020 |
| 6.7 (5.60 - 7.30) | 2014 | Survey/reported | Gower et al, 2014 |
| 7.7 (6.70 - 8.90) | 2015 | Survey/reported | Hagan et al, 2015 |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 69.1 (58 - 80.20) | 2015 | Modelled | Degenhardt L et al, 2017 |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 165,000 (120,000 - 169,000) | 2015 | Modelled | Blach et al, 2017 |
| 189,937 (152,918 - 235,373) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 191,404 (153,354 - 235,034) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 192,198 (154,875 - 234,789) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 192,355 (155,821 - 235,489) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 191,959 (155,566 - 234,776) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 191,192 (154,099 - 232,822) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 192,059 (157,301 - 230,852) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 194,991 (161,159 - 231,890) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 198,120 (165,530 - 233,978) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 199,776 (167,211 - 234,203) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 198,510 (166,486 - 233,951) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 194,557 (163,155 - 228,663) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 189,406 (159,242 - 222,052) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 183,813 (155,074 - 215,001) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 178,612 (150,457 - 208,512) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 174,581 (146,577 - 204,071) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 171,685 (145,181 - 200,552) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 169,239 (143,400 - 197,180) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 166,991 (141,558 - 195,124) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 164,699 (139,675 - 192,344) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 162,260 (137,494 - 189,867) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 157,662 (133,490 - 184,361) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 150,364 (127,073 - 177,511) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 142,472 (118,754 - 170,174) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 135,950 (112,294 - 164,208) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 132,637 (108,689 - 161,967) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 131,955 (107,415 - 160,551) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 131,275 (106,105 - 159,746) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 129,848 (105,058 - 157,905) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 127,352 (102,992 - 155,505) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 127,883 (103,502 - 156,065) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 48,600 | 2021 | Survey/reported | Georgia National Center for Disease Control and Public Health, 2022 |
| 150,000 | 2015 | Survey/reported | Hagan et al, 2019 |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 11,300 (8,200 - 11,500) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 10 (7.47 - 13.40) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 5.91 (4.30 - 8.07) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.07 (4.50 - 8.24) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.19 (4.65 - 8.42) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.23 (4.62 - 8.29) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.09 (4.53 - 8.07) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.01 (4.48 - 7.91) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.99 (4.46 - 7.94) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.73 (6 - 9.94) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.12 (5.46 - 9.19) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.36 (4.84 - 8.41) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.04 (6.36 - 10.19) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.07 (6.32 - 10.19) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.06 (6.37 - 10.21) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.12 (6.32 - 10.31) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.01 (6.23 - 10.16) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.84 (6.06 - 10.06) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.89 (6.11 - 10.02) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.82 (5.97 - 10.06) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.2 (6.25 - 10.52) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.86 (6.78 - 11.48) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.5 (6.49 - 10.97) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.11 (6.97 - 11.81) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.27 (7.09 - 11.99) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.52 (7.32 - 12.28) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.47 (7.33 - 12.30) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.71 (7.58 - 12.73) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.21 (7.79 - 13.52) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.08 (7.84 - 13.12) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.02 (7.47 - 13.36) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.18 (7.72 - 13.55) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 425 | 2016 | Modelled | WHO |
| 367 (274 - 490) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 367 (274 - 490) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 376 (286 - 501) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 381 (291 - 504) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 379 (295 - 494) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 368 (288 - 483) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 362 (281 - 471) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 367 (282 - 474) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 361 (276 - 467) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 359 (274 - 465) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 353 (270 - 457) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 343 (262 - 442) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 335 (256 - 430) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 324 (248 - 417) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 330 (255 - 424) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 338 (261 - 429) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 354 (276 - 450) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 356 (277 - 452) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 366 (287 - 463) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 374 (295 - 473) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 380 (301 - 482) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 373 (290 - 479) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 351 (269 - 452) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 319 (243 - 422) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 306 (227 - 405) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 312 (232 - 410) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 329 (243 - 437) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 326 (243 - 431) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 335 (252 - 456) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 332 (246 - 451) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 325 (237 - 445) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of persons initiating HCV treatment
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 52,594 | 2018 | Survey/reported | Georgia National Center for Disease Control and Public Health, 2022 |
| 64,537 | 2019 | Survey/reported | Georgia National Center for Disease Control and Public Health, 2022 |
| 69,192 | 2020 | Survey/reported | Georgia National Center for Disease Control and Public Health, 2022 |
Showing out of
Show more
Number of persons treated for HCV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 5,941 | 2015 | Survey/reported | WHO, 2018 |
| 21,654 | 2016 | Survey/reported | WHO, 2018 |
| 19,514 | 2016 | Survey/reported | Hep Test Webinar Presentation- Maia Alkhazashvili |
| 14,789 | 2017 | Survey/reported | Hep Test Webinar Presentation- Maia Alkhazashvili |
| 10,202 | 2018 | Survey/reported | Hep Test Webinar Presentation- Maia Alkhazashvili |
| 11,956 | 2019 | Survey/reported | Hep Test Webinar Presentation- Maia Alkhazashvili |
| 7,251 | 2020 | Survey/reported | Hep Test Webinar Presentation- Maia Alkhazashvili |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 31 (16 - 271) | 2015 | Survey/reported | Georgia National Centre for Disease Control and Public Health, 2015; Curatio International Foundation, 2015; Eurasia Harm Reduction Network, 2015 |
| 78 | 2021 | Survey/reported | Georgia Technical Adviosry Group |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.9 (3.10 - 4.80) | 2015 | Survey/reported | Curatio International Foundation, 2015 |
Proportion of persons living with HCV diagnosed
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.6 | 2020 | Survey/reported | Georgia National Center for Disease Control and Public Health, 2022 |
Price of HCV cure (Average price in public sector for 3 months of DAAs)
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HBV elimination goal
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based, Birth cohort
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None
Overview
HBV elimination goal
HCV elimination goal
Year of goal
2030
Prevalence (national)
Modelled
Survey/surveillance
Hepatitis related deaths (national)
Modelled
HBV
367
2019
(268 - 493)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
367
2019
(274 - 490)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Eligible for HBV generic medicines
Eligible for HCV generic medicines
